This brand name is authorized in Brazil, Singapore, Spain.
The drug NIULIVA contains one active pharmaceutical ingredient (API):
1
|
UNII
XII270YC6M - HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN
|
|
Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J06BB04 | Hepatitis B immunoglobulin | J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 510918120005407, 510918120005507, 510918120005607, 510918120005707 |
| ES | Centro de información online de medicamentos de la AEMPS | 69770 |
| SG | Health Sciences Authority | 14068P, 14069P, 14070P |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.